Adverse events among pulmonary drug-resistant tuberculosis patients in Banten, Indonesia

Penulis

  • Mita Restinia Department of Pharmacy, Faculty of Health Sciences, Universitas Islam Negeri Syarif Hidayatullah Jakarta, Tangerang Selatan, 15412, Banten, Indonesia ,
  • Alyya Siddiqa Department of Pharmacology, Faculty of Medicine, Universitas Islam Negeri Syarif Hidayatullah Jakarta, Tangerang Selatan, 15412, Banten, Indonesia ,
  • Wulan Purnama Sari Department of Pharmacy, Faculty of Health Sciences, Universitas Islam Negeri Syarif Hidayatullah Jakarta, Tangerang Selatan, 15412, Banten, Indonesia ,

DOI:

https://doi.org/10.35814/jifi.v23i1.1704

Kata Kunci:

Adverse events, drug-resistant tuberculosis, treatment outcome

Abstrak

Drug-resistant Tuberculosis (DR-TB) treatment requires an extended duration, making adverse events (AEs) a common concern. This study aimed to assess the frequency of AEs, time to events, and their association with treatment outcomes among DR- pulmonary TB patients. A retrospective cohort study was conducted on patients aged >18 years at one of public hospitals at Tangerang, Banten, Indonesia, from March 2021 to May 2023. Bivariate analysis was used to analyze the association between AEs and treatment outcomes. Among 53 patients included in the study, all experienced at least one AEs. Number of AEs mean ± SD; 9.724±4.86. Mild AEs were reported in 100% of patients, while 75.5% experienced moderate AEs, and 81.1% experienced severe AEs. The most common AEs included nausea (90.6%), anemia (73.6%), vomiting (62.3%), decreased appetite (60.4%), and joint pain (60.4%). The AEs were frequently reported during intensive phase (4-6 months). AEs have association with treatment outcome (P<0.05).  The frequency of AE among DR-TB patients was high. Early detection and effective management of AEs are essential to improving treatment outcomes for DR-TB patients.

Referensi

Unduhan

Diterbitkan

2025-04-30

Terbitan

Vol 23 No 1 (2025): JIFI

Bagian

Articles

Lisensi

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.